title: Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  The effects of pioglitazone hydrochloride monotherapy on abnormal lipid control were evaluated in Japanese patients with type 2 diabetes mellitus, comparing with glibenclamide monotherapy.
  
  
  METHODS
  Patients were randomly assigned to receive, once daily, pioglitazone hydrochloride, at 15 mg or 30 mg (n=46), or glibenclamide, at 1.25 mg or 2.5 mg (n=46). The 24-week study included patients with type 2 diabetes having high levels of triglyceride (TG).
  
  
  RESULTS
  Pioglitazone hydrochloride produced beneficial effects on dyslipidemia in patients with type 2 diabetes, compared with the baseline and the glibenclamide group, as demonstrated by increases in high-density lipoprotein cholesterol (HDL-C) levels and low-density lipoprotein cholesterol (LDL) particle size, a fall in TG levels, and an increased ratio of visceral to subcutaneous fat volumes (V/S). Pioglitazone hydrochloride reduced fasting serum insulin levels, with low fasting plasma glucose (FPG) and glycohemoglobin levels, compared to the baseline, suggesting an improvement of insulin resistance.
  
  
  CONCLUSIONS
  As expected, glibenclamide reduced FPG levels through increased insulin secretion. Pioglitazone hydrochloride and glibenclamide were well tolerated. Pioglitazone hydrochloride improved dyslipidemia related to insulin resistance, whereas glibenclamide enhanced insulin secretion, with only a minor effect on lipid control, in Japanese patients with type 2 diabetes.
authors.affiliation: Department of Internal Medicine, School of Medicine, Teikyo University, Kaga, Tokyo, Japan. ttera@med.teikyo-u.ac.jp
authors.forename: Tamio
authors.initials: T
authors.lastname: Teramoto
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Yamada
authors.forename: Kohji
authors.initials: K
authors.lastname: Shirai
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Saito
mesh_terms: D000368:Aged; D044466:Asian People; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005215:Fasting; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D050151:Subcutaneous Fat / Q000187:drug effects / Q000503:physiopathology; D045162:Thiazolidinediones / Q000008:administration & dosage*; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014280:Triglycerides; D000077205:Pioglitazone